Back to medications
Medication monograph

alirocumab

PCSK9 InhibitorsLipid-Lowering AgentsHypolipidemic Agents Indicated for HyperlipidemiaPCSK9 Inhibitor

Clinical reference

Product monograph

PRALUENT- alirocumab injection, solution

Brands & formulations

Family members

PRALUENT

Marketed
75 MGSUBCUTANEOUSSOLUTION[ "alirocumab" ]
Product monograph

PRALUENT

Marketed
150 MGSUBCUTANEOUSSOLUTION[ "alirocumab" ]
Product monograph

PRALUENT

Marketed
300 MGSUBCUTANEOUSSOLUTION[ "alirocumab" ]
Product monograph

Pricing

Price information

Praluent Single Use Pen Injection x 2 - Local Pickup Only

Sanofi Aventis · 75 mg/ml

1: $1217.13

Praluent Single Use Pen Injection x 2 - Local Pickup Only

Sanofi Aventis · 150 mg/ml

1: $1217.13

Classification

Chemical class
PCSK9 Inhibitors
Clinical class
Lipid-Lowering Agents
Banks class
Hypolipidemic Agents Indicated for Hyperlipidemia, PCSK9 Inhibitor